R&D channel feed

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

18 hours ago
Cell/Gene Tx

Arc­turus to pri­or­i­tize mR­NA ther­a­peu­tics in bid to boost rare dis­ease pro­grams

Yesterday

Cy­to­ki­net­ics gets an 'in­cre­men­tal' win for de­layed heart drug

Yesterday

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Yesterday

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

2 days ago

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

2 days ago

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

3 days ago
Pharma

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

5 days ago

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

5 days ago

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

6 days ago
Cell/Gene Tx
In Focus

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

6 days ago

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

Last week
Pharma
Manufacturing

Theri­va’s on­colyt­ic virus suc­ceeds in pan­cre­at­ic can­cer study, but stock falls

Last week

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

Last week
Cell/Gene Tx

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

Last week

Marea heads to Phase 2b af­ter up­dat­ed bio­mark­er da­ta show CV drug’s promise

Last week

Ver­tex paus­es study of mR­NA ther­a­py for cys­tic fi­bro­sis

Last week

Aldeyra plots third FDA fil­ing for dry eye dis­ease drug af­ter lat­est Phase 3 da­ta

Last week

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

Last week

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

Last week
Pharma
FDA+

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

Last week
AI

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

Last week
Cell/Gene Tx

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Last week
China
Cell/Gene Tx

Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease

Last week
1234 Next page Last page
A service from the Financial Times